Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
A method for at least one of characterizing, diagnosing and treating a neurological health issue in at least a subject, the method comprising: receiving an aggregate set of biological samples from a population of subjects; generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset for the population of subjects; generating a characterization of the neurological health issue based upon features extracted from at least one of the microbiome composition dataset and the microbiome functional diversity dataset; based upon the characterization, generating a therapy model configured to correct the neurological health issue; and at an output device associated with the subject, promoting a therapy to the subject based upon the characterization and the therapy model.
1. A method for at least one of characterizing, diagnosing, and treating an anxiety condition of a subject, the method comprising:
receiving an aggregate set of samples from a population of subjects comprising at least one subject associated with the anxiety condition;
for each sample of the aggregate set of samples:
determining a microorganism nucleic acid sequence, comprising:
fragmenting nucleic acid material of the sample,
amplifying the fragmented nucleic acid material with a primer, and
determining an alignment of the microorganism nucleic acid sequence to a reference nucleic acid sequence;
generating a microbiome feature dataset for the population of subjects based upon the alignments;
generating a characterization of the anxiety condition based upon the microbiome feature dataset;
based upon the characterization, generating a therapy model that determines a therapy for correcting the anxiety condition; and
at an output device associated with the subject, providing the therapy to the subject with the anxiety condition based upon the characterization and the therapy model.
2. The method of claim 1 , wherein determining the microorganism nucleic acid sequence comprises selecting the primer for the nucleic acid sequence associated with the anxiety condition based upon a primer selection model.
3. The method of claim 2 , wherein determining the microorganism nucleic acid sequence comprises performing, at a library preparation subsystem, multiplex amplification with the fragmented nucleic acid material based on the primer.
4. The method of claim 1 , further comprising: from the population of subjects, generating a supplementary dataset informative of a characteristic associated with the anxiety condition; and wherein generating the characterization of the anxiety condition is further based on the supplementary dataset.
5. The method of claim 1 , wherein generating the characterization of the anxiety condition is further based upon a set of criteria described in a manual of mental disorders.
6. The method of claim 1 , wherein the microbiome feature dataset includes at least one of: a microbiome taxonomic feature portion, a microbiome composition diversity feature, a microbiome functional diversity feature, and a microbiome functional feature portion.
7. The method of claim 1 , wherein generating the characterization of the anxiety condition comprises evaluating features of the microbiome feature dataset associated with a set of taxonomic features derived from at least one of: Sarcina (genus), Bacteroides (genus), Sutterella (genus), and Dorea (genus).
8. The method of claim 7 , wherein the set of taxonomic features comprises features associated with at least one of: Terrisporobacter (genus), Moryella (genus), Blautia (genus), Lactobacillus (genus), and Parabacteroides (genus).
9. The method of claim 1 , wherein generating the characterization of the anxiety condition comprises evaluating features of the microbiome feature dataset associated with a set of functional features derived from at least one of: a carbohydrate metabolism derived feature, a translation derived feature, and a genetic information processing derived feature.
10. The method of claim 9 , wherein the set of functional features further comprises features associated with at least one of: a biosynthesis of other secondary metabolites derived feature, a metabolism derived feature, and a replication and repair derived feature.
11. A method for at least one of characterizing, diagnosing, and treating an anxiety condition of a subject, the method comprising:
receiving a sample from the subject associated with the anxiety condition;
determining nucleic acid sequences of a microorganism component of the sample, comprising: amplifying nucleic acid material of the sample with a primer;
determining alignments of the nucleic acid sequences to reference nucleic acid sequences;
generating a microbiome feature dataset for the subject based upon the alignments;
generating a characterization of the anxiety condition in the subject upon processing the microbiome feature dataset with a characterization model derived from a population of subjects; and
at an output device associated with the subject, providing a therapy to the subject with the anxiety condition upon processing the characterization with a therapy model, wherein the therapy comprises a microbiome-modifying therapy operable to improve the anxiety condition in the subject.
12. The method of claim 11 , wherein determining nucleic acid sequences further comprises selecting the primer for the nucleic acid sequence with a primer selection model.
13. The method of claim 11 , wherein receiving the sample from the subject comprises providing a sampling kit to the subject at a remote location, the sampling kit including a sample container having a pre-process reagent component and configured to receive a sample from a collection site of the subject.
14. The method of claim 11 , wherein generating the characterization comprises evaluating features of the microbiome feature dataset associated with at least one of Sarcina (genus), Bacteroides (genus), and Sutterella (genus).
15. The method of claim 14 , wherein generating the characterization comprises evaluating features of the microbiome feature dataset associated with at least one of:
Dorea (genus), Terrisporobacter (genus), and Moryella (genus).
16. The method of claim 15 , wherein generating the characterization comprises evaluating features of the microbiome feature dataset associated with at least one of Blautia (genus), Lactobacillus (genus), and Parabacteroides (genus).
17. The method of claim 11 , wherein generating the characterization comprises evaluating features of the microbiome feature dataset associated with at least one of: carbohydrate metabolism, translation, and genetic information processing.
18. The method of claim 17 , wherein generating the characterization comprises evaluating features of the microbiome feature dataset associated with at least one of: biosynthesis of other secondary metabolites, metabolism, and replication and repair.
19. The method of claim 11 , wherein providing the microbiome-modifying therapy comprises providing a consumable to the subject, the consumable affecting a microorganism component that selectively supports modulation of microbiome function in the subject, associated with correction of the anxiety condition, based on the therapy model.
20. The method of claim 11 , wherein providing the therapy comprises providing instructions to the subject regarding setup of a user account within a social networking system configured to provide microbiome-derived insights to the subject, and transmitting diagnostic information and behavioral therapeutic techniques, associated with correcting the anxiety condition, through the social networking system.